



US006610270B1

(12) **United States Patent**
Ajami

(10) **Patent No.:** **US 6,610,270 B1**
(45) **Date of Patent:** ***Aug. 26, 2003**

(54) **IN VIVO DETERMINATION OF METABOLIC FUNCTION FOR USE IN THERAPY MANAGEMENT**

(75) Inventor: **Alfred M. Ajami**, Brookline, MA (US)

(73) Assignee: **Xanthus Life Sciences, Inc.**,
Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/719,956**

(22) PCT Filed: **Jun. 29, 1999**

(86) PCT No.: **PCT/US99/14725**

§ 371 (c)(1),
(2), (4) Date: **Dec. 18, 2000**

(87) PCT Pub. No.: **WO00/00636**

PCT Pub. Date: **Jan. 6, 2000**

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/107,965, filed on Jun. 30, 1998, now Pat. No. 6,284,219.

(51) **Int. Cl.**⁷ **A61K 49/00**

(52) **U.S. Cl.** **424/9.2**; 424/1.81; 424/1.11;
435/4

(58) **Field of Search** 424/1.11, 1.53,
424/1.65, 1.81, 9.2, 9.1; 435/4, 183, 188,
814; 250/472.1; 600/9

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,449,688 A 9/1995 Wahl et al.
6,284,219 B1 * 9/2001 Ajami 424/1.11

FOREIGN PATENT DOCUMENTS

DE 26 26 533 A 12/1977 G21H/5/02
EP 0 825 260 A 2/1998 C12N/15/55
EP 0 826 377 A 3/1998 A61K/49/00
WO WO 93 05780 A 4/1993 A61K/31/45

OTHER PUBLICATIONS

Rogers et al., "In vivo synthesis and utilization of arginine in the rat", *Amer. J. Physiol.*, vol 223, No 1 pp. 236-240.
Harmeyer et al., "The metabolic conversion of arginine in the rumen wall and its importance in ruminant nitrogen metabolism", *Isotope Stud. Nitrogen Chain, Proc. Symp., Vienna, Vol. Meeting Date 1967*, pp. 265-274.
Arythunyan et al., "Effects of thyroid hormones on liver arginase activity in rats" *Biol Zh. Arm.*, vol. 37, No. 5, pp. 416-419.
Tramell et al., "Arginine and urea metabolism in the South American land snail, *Stropocheilus oblongus*", *Comp. Biochem. Physiol.*, vol. 42, No. 3 p. 445.

Birkner et al., "The influence of hyperthermia on ornithine carbamolytransferase and arginase activity in liver or rats", *Ann. Acad. Med. Silesiensis*, vol. 24, pp. 13-17.

Nettleton et al., "Reutilization of guanido-labeled arginine in rat liver proteins and the influence of diet", *J. Nutr.*, vol. 104, No. 7, pp. 916-921.

Levillain et al., "Production of urea from arginine in pars recta and collecting duct of the rat kidney", *Renal Physiol. Biochem.* vol. 12, No. 5-6, pp. 302-312.

Klein et al., "Increased arginase activity during lymphocyte mitogenesis", *Biochem. Biophys. Res. Commun.*, vol. 81, No. 1, pp. 199-204.

Nishibe, H., "Ultramicromethod for the determination of human arginase in the presence of urea", *Clin. Chim. Acta*, Sep. 20, 1976, vol. 71, No. 3, pp. 413-8.

Ruegg et al., "A rapid and sensitive assay for arginase", *Analytical Biochemistry*, vol. 102, No. 1, pp. 206-212.

Snejdarkova et al., "Model arginine dynamics in the Japanese quail coturnix-coturnix-japonica -1, time dependent arginine concentration changes in selected compartments", *Nutrition Reports International*, vol. 28, No. 4, pp. 753-760.

Pratzel et al., "Biochemistry of free amino acids in the stratum corneum of human epidermis", *Arch. Dermatol.*, vol. 259, No. 2 pp. 151-156.

Carl et al., "Manganese and epilepsy brain glutamine synthetase and liver arginase activities in genetically epilepsy prone and chronically seized rats", *Epilepsia*, US, Raven Press Ltd., NY, vol. 34, No. 3 pp. 441-446.

* cited by examiner

Primary Examiner—Dameron L. Jones

(57) **ABSTRACT**

It is an object of the present invention to provide in vivo analytical methods that allow for diagnosis and management of therapy for diseases involving discrete biochemical pathways. In the method of the invention, a labelled tracer probe, a specifically designed substrate of a "gateway" enzyme, an enzyme marking a regulatory point in a discrete biochemical pathway, is administered to a subject; a labelled product of the action of the enzyme is measured; and the appearance and concentration of the product are related to the disease condition of interest. Determination of the rate of substrate-product conversion of the gateway enzyme allows for the analysis to be made. The method involves administering a defined amount of a labelled "metaprobe" substrate of the gateway enzyme to a subject, at a site that provides access to a desired pool of the gateway enzyme in the subject, and measuring the amount of the chosen labelled product. The presence and amount of the chosen labelled product in, e.g., the breath, definitely indicates that the labelled metaprobe has been metabolized by the specific enzyme in the specific biochemical pathway under consideration, and from the calculated rate of substrate-product conversion by the gateway enzyme, the desired diagnostic determination may be made. Likewise, if a specific therapeutic treatment for a disease is underway with a patient, this method allows for a minimally invasive assessment of the effectiveness of the treatment, with minimal discomfort to the patient.

12 Claims, 25 Drawing Sheets